This executive summary, excerpted from AVAC Report 2014/15, puts the current discussion about global targets for ending AIDS in context. What makes a good target? What targets have worked in the past—and why? What is the state of HIV prevention targets and plans today?
AVAC Report 2014/15: Prevention on the Line [Executive Summary]
Essential Actions for HIV Prevention Research Rollout 2014/15
This updated version of AVAC’s 3D graphic shows priorities across the research-to-rollout spectrum. The graphic appears in AVAC Report 2014/15: Prevention on the Line.
FY2015 US Global AIDS Budget Plan: The Human Impact
The US government’s efforts to fight the global AIDS pandemic through both the US President’s Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund to Fight AIDS, Tuberculosis and Malaria have been transformative in the global AIDS response. To maintain the current total level of US global HIV/AIDS funding in Fiscal Year 2015, the US House of Representatives has proposed restoring US$300 million in PEPFAR funding. As illustrated in this infographic, amfAR has estimated the potential human impact of US$300 million to expand lifesaving HIV prevention, Treatment U=U and care services.
Increasing National Impact and Uptake of Good Participatory Practice Guidelines for Biomedical HIV Prevention (GPP): Three Country Case Studies
GPP provides a systematic framework for stakeholder engagement. This infographic examines how GPP was applied to the national trial oversight process in three countries: Uganda, Thailand, and South Africa. The timline plots key GPP activities and milestones from 2011-2014. This poster was presented at the 2014 HIV Research for Prevention conference in South Africa.
The Tipping Point: Moving From Rhetoric to Real Milestones for Ending AIDS
One way to measure progress in fighting AIDS is to compare the number of new HIV infections with the increase in HIV positive people on antiretroviral therapy (ART) over a given time period. An AIDS epidemic reaches its “tipping point” when the number of annual new HIV infection falls below the annual increase in patients starting ART. This poster was presented at the 2014 HIV Research for Prevention Conference in South Africa.
HIV Cure Research – An introductory fact sheet
This introductory 2-page document defines cure, reviews the scientific evidence to date, and outlines key research strategies currently being pursued. This fact sheet is part of a series on emerging HIV prevention strategies.
Px Wire July-September 2014, Vol. 7, No. 3
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. This issue comes out on the eve of the International AIDS Conference in Melbourne, Australia—and we begin with “AVAC’s Take” on key messages and commitments to look for at and after the meeting. We also call for more PrEP demonstration projects and provide an update of the proposed ECHO trial.
Px Wire October-December 2014, Vol. 7, No. 4
Px Wire is AVAC’s quarterly update covering the latest in the field of biomedical HIV prevention research, implementation and advocacy. In this issue, we offer a selective “state of the union” update on various areas of the prevention field—highlighting key developments, messages and areas of work that warrant particular joint attention at the first HIV Research for Prevention (HIV R4P) conference and beyond.
PrEP for Black Gay and Bi-sexual Men in the US: What you need to know
This factsheet includes information on accessing and paying for PrEP, side effects and outlines key information on the relevance of PrEP for Black gay and bisexual men.
Good Participatory Practice: Guidelines for TB Drug Trials
The Good Participatory Practice (GPP) guidelines for TB Drug Trials is the product of a collaboration between AVAC and the Stakeholder and Community Engagement Workgroup of the Critical Path to TB Drug Regimens. The guidelines offer trial funders, sponsors, and implementers systematic guidance on how to engage stakeholders throughout the research lifecycle. This first edition, published in 2012, contains five sections that provide context, foundational principles, and key practices for conducting TB drug trials.